Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Bottom-Up

IKang Healthcare Group (ADR) / Equity Bottom-Up

<p>The consortium led by Jiangsu Sanyou (parent of KANG competitor Meinian Onehealth) today raised its non-binding cash offer for iKang to US$23.50/ADS from US$22 (Chinese press release attached). The new offer values the company at 23.1x trailing EBITDA and 4.8x trailing revenue, up from 21.6x and 4.5x, respectively. The higher offer is closer to the US$25-26/ADS that we had discussed in our previous Insights <a href="https://www.smartkarma.com/insights/never-leave-an-opening" target="_blank" data-smartkarma-citation="insights:1972">Never Leave an Opening</a> and <a href="https://www.smartkarma.com/insights/a-buyout-offer-that-needs-improvement" target="_blank" data-smartkarma-citation="insights:1274">A Buyout Offer That Needs Improvement</a> .</p><p>The offer increases the…</p>

The consortium led by Jiangsu Sanyou (parent of KANG competitor Meinian Onehealth) today raised its non-binding cash offer for iKang to US$23.50/ADS from US$22 (Chinese press release attached). The new offer values the company at 23.1x trailing EBITDA and 4.8x trailing revenue, up from 21.6x and 4.5x, respectively. The higher offer is closer to the US$25-26/ADS that we had discussed in our previous Insights Never Leave an Opening and A Buyout Offer That Needs Improvement .The offer increases the…

Meinian Onehealth Healthcare H (002044 CH)

Jiangsu Sanyou Group Raises Bid to US$23.50/ADS